Findings from the phase 3 KEYNOTE-A18 trial showed that pembrolizumab plus chemoradiotherapy improved overall survival in newly diagnosed cervical cancer compared with chemoradiotherapy alone.
Sabrina Serani
Sabrina Serani is the assistant managing editor for Targeted Oncology.
Articles by Sabrina Serani
The Oncologic Drug Advisory Committee of the FDA found that imetelstat has robust data supporting its use for transfusion-dependent anemia in patients with myelodysplastic syndromes.
The FDA has accepted the new drug application of ensartinib for the treatment of patients with metastatic ALK-positive non-small cell lung cancer.
Introducing a checkpoint inhibitor like nivolumab for patients where chimeric antigen receptor T-cell therapy failed in multiple myeloma is a potential area of interest for researchers.
Pedro Barata, MD, MSc, discussed the importance of the NRG Oncology Semiannual Meeting and the forum it provides for oncologists to collaborate and optimize cancer treatment.
Findings from the phase 3 ECHELON-3 trial demonstrated that brentuximab vedotin plus lenalidomide and rituximab led to improvements in overall survival among patients with diffuse large B-cell lymphoma.
Findings from a post hoc analysis of lurbinectedin for the treatment of small cell lung cancer showed that the agent was more effective and less toxic than topotecan.
Following changes to the manufacturing process, the phase 1 study of NX-2127 in B-cell malignancies has been cleared to continue by the FDA.
Identifying differences in pancreatic cancer subtypes could be at the center of developing targeted treatments in this challenging disease.
Jeremy Ramdial, MD, discussed a phase 1/2 study investigating the GemCloBu conditioning regimen for stem cell transplants in aggressive lymphomas.
Christopher Flowers, MD, MS, discussed the phase 2 ROSEWOOD trial, the study that supported the FDA accelerated approval of zanubrutinib and obinutuzumab for the treatment of relapsed/refractory follicular lymphoma.
In a matched indirect comparison of zanubrutinib vs acalabrutinib, the former showed survival and response improvements in patients with chronic lymphocytic leukemia.
The combination of a novel mTORC1/2 inhibitor with paclitaxel could present a new way of targeting metastatic or persistent endometrial cancer.
The FDA has approved inotuzumab for the treatment of pediatric patients 1 year or older with acute lymphoblastic leukemia.
Third-line combination of THIO and cemiplimab improved overall response rate compared with standard of care in patients with non-small cell lung cancer.
Balancing cost and efficiency remains at the crux of autologous stem cell transplants for multiple myeloma treatment.
The FDA orphan drug designation qualifies the sponsor of avutometinib for tax credits for clinical trials, exemption from user fees, and potential market exclusivity.
The National Comprehensive Cancer Network has included ArteraAI in its clinical practice guidelines as a predictive test for localized prostate cancer.
The first-in-human study that has received FDA clearance will investigate the novel autologous Innocell vaccine in stage III/IV ovarian cancer.
In an interview with Targeted Oncology, Reshma Mahtani, DO, discussed findings from a retrospective study exploring treatment options for geriatric patients with HER2-positive breast cancer.
The novel cell therapy A2B530 is the first logic-gated cell therapy aimed at selectively killing tumor cells and protecting healthy cells in colorectal cancer.
Alex Chehrazi-Raffle, MD, discussed a real-world analysis of clinical characteristics of patients with bladder cancer receiving adjuvant nivolumab or chemotherapy.
Following the development of further safety and monitoring protocols, the IOV-LUN-202 trial can resume patient enrollment.
Hedyeh Ebrahimi, MD, discussed a novel approach to targeting metastatic renal cell carcinoma through a microbiome-mediated pathway.
Amivantamab plus carboplatin and pemetrexed is now an approved first-line treatment for patients with EGFR exon 20 insertion mutation-positive non-small cell lung cancer.
In an interview with Targeted Oncology, Reshma Mahtani, DO, discussed findings of a quality improvement initiative identifying challenges for health care professionals and patients with HER2-positive breast cancer.
Alice Bertaina, MD, discussed combining T-allo10 gene therapy with stem cell transplants for the treatment of pediatric and young adult patients with hematologic malignancies.
The natural killer cell therapy IDP-023 is being studied in a phase 1 trial for the treatment of patients with non-Hodgkin lymphoma and multiple myeloma.
Ropeginterferon alfa is now a recommended first-line treatment for patients with polycythemia vera, according to the National Comprehensive Cancer Network’s updated guidelines.
The FDA has granted a breakthrough therapy designation to BAY 2927088 for the treatment of non-small cell lung cancer harboring HER2-activating mutations.